Industry
Industry — China Beauty (Color Cosmetics & Skincare)
Figures converted from CNY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
China beauty is the world's second-largest beauty market — a $56 billion-plus arena of cosmetics, skincare and personal-care products sold mostly through e-commerce, mostly to female consumers in tier-1 to tier-3 cities. The economics are simple but punishing: gross margins are 65–80%, but acquiring a Chinese beauty customer through Douyin live streams, Tmall search, and KOL endorsements eats 50–70% of revenue, so net margins for digitally native brands are thin or negative. The structure is fragmented (no single player holds even a high-single-digit share), the cycle is set by consumer confidence and platform traffic costs, and the rules of the game are rewritten every 18 months by the NMPA and Chinese e-commerce platforms.
The one thing newcomers usually misunderstand: this is not a "premium global brand" industry like the one L'Oréal and Estée Lauder dominate worldwide. In China, science-backed domestic brands are taking share from global majors, and the winners are companies that can manufacture biotech-grade skincare in Guangzhou and convert Douyin live streams into measurable repurchase. Yatsen — which owns Perfect Diary, Galénic and DR.WU — is one of the listed pure-plays on that thesis, currently sub-scale relative to leader Proya and still unprofitable on a GAAP basis.
1. Industry in One Page
The brand owner sees gross margin and the marketing bill. The platform sees take rate and ad inventory. The KOL takes a commission on every livestream sale. Read the rest of the report knowing that the beauty group only keeps the margin left after the platform, the KOL, and the customer-acquisition machine have all been paid.
2. How This Industry Makes Money
Beauty groups sell branded SKUs at 4–10× COGS, but the cost structure does not stop at COGS. To get a Chinese consumer to try a new SKU on Douyin or Tmall, brand owners pay platform ad fees, KOL commissions, livestream host fees, free samples, and shopping-festival discounts. The 70%+ gross margin is real — but so is a 60%+ selling-and-marketing line.
Three takeaways from the stack. First, gross margin is genuine — Chinese ODM/OEM (Cosmax, Intercos) and proprietary formulations can land COGS at 20-30% of net revenue. Second, the gross profit is rented from the platforms and the KOLs — Yatsen's selling and marketing line absorbed roughly two-thirds of revenue in 2025 even after disciplined cost-cutting. Third, the gap between a profitable masstige operator (e.l.f., 4.5% operating margin in FY26) and a sub-scale Chinese brand-builder (Yatsen, –4.3%) lives almost entirely in selling and G&A intensity, not in COGS or R&D.
Bargaining power sits with the platforms and the consumer. Tmall and Douyin set the cost of traffic; consumers can switch brands at essentially zero friction. Brand owners earn back power only through proprietary actives, scientific claims that survive NMPA filing, and the ability to launch hit SKUs ("Biolip Essence Lipstick," "DR.WU Mandelic Acid Serum") that drive repurchase rather than one-time trial.
3. Demand, Supply, and the Cycle
Where the cycle bites first: volume in color cosmetics. Color is a discretionary, trend-driven category with short replenishment cycles — when consumers feel poorer or platform traffic spikes in cost, color volumes fall before skincare. Yatsen's own history makes the cyclicality concrete: revenue compounded from $92M in 2018 to $919M in 2021 as Perfect Diary captured the Douyin and KOL boom, then contracted to $481M by 2023 when post-COVID Chinese consumer confidence weakened and platform traffic costs rose. Skincare is more defensive — the routine creates repurchase — which is why every listed Chinese beauty house is racing to shift mix into skincare.
The lesson from one cycle: a 65%+ peak-to-trough revenue range is plausible for a sub-scale digitally native brand operator, because both demand (consumer confidence) and supply economics (platform traffic cost) move against the brand owner in the downturn.
4. Competitive Structure
The structure is best understood as "fragmented and re-fragmenting." MarketScreener's published sector view shows L'Oréal at roughly $233 billion in market cap, Shiseido at ~$6.5 billion, Amorepacific at ~$4.2 billion — and the entire listed Chinese cohort (Proya $3.85B, Chicmax ~$3.0B, Yatsen ~$273M) sitting well below the global majors but growing faster within China. Historical Kantar share data put Proya at 1.0% and Shanghai Jahwa at 1.9% of the China cosmetics market in 2017; even after a decade of growth, no single listed Chinese house holds more than mid-single-digit share of the China beauty market. That is structurally important: it means competition is brand-by-brand and category-by-category, not by aggregate scale, and it means a sub-scale player like Yatsen still has room to compound if it can find one or two hit brands.
The competitive dynamic that matters: domestic Chinese brands collectively captured nearly 60% of the China beauty market by 2025 (per a May 2026 Yatsen-cited CGTN figure), reversing the prior decade's foreign-brand dominance. Inside that domestic 60%, the fight is between Proya's scale-and-skincare playbook (95% online, $1.5B revenue, growing) and Yatsen's multi-brand-portfolio playbook (color heritage, skincare pivot, restructuring) — with Chicmax, Botanee and a long tail of private brands harassing both.
5. Regulation, Technology, and Rules of the Game
Three regulatory ideas the reader should hold onto. First, NMPA filing is a real moat — "special cosmetics" (sunscreen, whitening, anti-aging claims, anti-hair-loss) require pre-market registration with the National Medical Products Administration, with claims backed by science. That gates the fast-fashion model of throwing untested SKUs at Douyin. Second, the Livestreaming E-Commerce Measures (Feb 2026) materially raise the cost of the marketing playbook that built brands like Perfect Diary — pre-broadcast script and prop review, explicit liability for hosts and MCNs, and platform compliance review change the marginal economics of every livestream. Third, YSG is a Chinese VIE-structured Cayman holding company listed on the NYSE — HFCAA delisting risk, CSRC offshore-listing rules, and the residual uncertainty of the VIE structure are industry-wide for ADR holders and live in the discount rate, not the income statement.
Technology shifts that are reshaping the economics: AI-driven ingredient discovery and formulation (cited explicitly by Yatsen and dcfmodeling); biomimetic delivery systems (Biotec™, SmartLock™); microbiome-based actives; and the migration of demand generation from Tmall search to short-video discovery (Douyin, RedNote). Each shift rewards R&D and scientific credibility over trend-marketing.
6. The Metrics Professionals Watch
The two metrics that matter most: selling and marketing as a percent of revenue, and skincare revenue share. The first tells you whether the brand owner is being squeezed by platforms and KOLs (i.e., the cost of demand generation). The second tells you whether the portfolio is shifting toward the defensive, higher-margin, higher-repurchase category. A Chinese beauty company can fake operating leverage by skipping R&D or by capitalizing marketing, but it cannot fake these two ratios.
7. Where Yatsen Holding Ltd Fits
Yatsen is a sub-scale, multi-brand Chinese beauty house mid-way through a strategic pivot. It is not the industry leader (Proya is), not a moated incumbent (no Chinese beauty company is), and not yet a profitable masstige model (e.l.f. is the global proof point at $1.6B revenue and 4.5% operating margin). It is something narrower: a credible Chinese house with a portfolio bet on science-backed skincare and a few real hero SKUs, trying to grow into its cost base before the cycle turns again.
8. What to Watch First
If three or more of the first four signals turn positive in the same two-quarter window, the industry backdrop for Yatsen is improving and the equity story tightens around skincare share and marketing leverage. If signals five through seven move against the company — regulatory drag, delisting risk crystallizing, no SKU pipeline — the equity story stays a 2026-into-2027 cyclical recovery trade rather than a structural compounder.